Frontiers in Microbiology (Sep 2024)

Global progress in clinical research on human respiratory syncytial virus vaccines

  • Ruofan Peng,
  • Chenghao Chen,
  • Qian Chen,
  • Yuwen Zhang,
  • Renjin Huang,
  • Yanjun Zhang,
  • Jianhua Li

DOI
https://doi.org/10.3389/fmicb.2024.1457703
Journal volume & issue
Vol. 15

Abstract

Read online

Human respiratory syncytial virus (hRSV) not only affects newborns but also older adults, contributing to a substantial worldwide burden of disease. However, only three approved hRSV vaccines remain commercially available to date. The development of a safe, practical and broad-spectrum vaccine suitable for all age groups remains extremely challenging. Using five different approaches—live-attenuated, recombinant-vector, subunit, particle-based, and mRNA—nearly 30 hRSV vaccine candidates are currently conducting clinical trials worldwide; moreover, > 30 vaccines are under preclinical evaluation. This review presents a comprehensive overview of these hRSV vaccines along with prospects for the development of infectious disease vaccines in the post-COVID-19 pandemic era.

Keywords